Mixed-location Cerebral Hemorrhage/microbleeds: Underlying Microangiopathy and Recurrence Risk
Authors
Affiliations
Objective: To assess the predominant type of cerebral small vessel disease (SVD) and recurrence risk in patients who present with a combination of lobar and deep intracerebral hemorrhage (ICH)/microbleed locations (mixed ICH).
Methods: Of 391 consecutive patients with primary ICH enrolled in a prospective registry, 75 (19%) had mixed ICH. Their demographics, clinical/laboratory features, and SVD neuroimaging markers were compared to those of 191 patients with probable cerebral amyloid angiopathy (CAA-ICH) and 125 with hypertensive strictly deep microbleeds and ICH (HTN-ICH). ICH recurrence and case fatality were also analyzed.
Results: Patients with mixed ICH showed a higher burden of vascular risk factors reflected by a higher rate of left ventricular hypertrophy, higher creatinine values, and more lacunes and severe basal ganglia (BG) enlarged perivascular spaces (EPVS) than patients with CAA-ICH (all < 0.05). In multivariable models mixed ICH diagnosis was associated with higher creatinine levels (odds ratio [OR] 2.5, 95% confidence interval [CI] 1.2-5.0, = 0.010), more lacunes (OR 3.4, 95% CI 1.7-6.8), and more severe BG EPVS (OR 5.8, 95% CI 1.7-19.7) than patients with CAA-ICH. Conversely, when patients with mixed ICH were compared to patients with HTN-ICH, they were independently associated with older age (OR 1.03, 95% CI 1.02-1.1), more lacunes (OR 2.4, 95% CI 1.1-5.3), and higher microbleed count (OR 1.6, 95% CI 1.3-2.0). Among 90-day survivors, adjusted case fatality rates were similar for all 3 categories. Annual risk of ICH recurrence was 5.1% for mixed ICH, higher than for HTN-ICH but lower than for CAA-ICH (1.6% and 10.4%, respectively).
Conclusions: Mixed ICH, commonly seen on MRI obtained during etiologic workup, appears to be driven mostly by vascular risk factors similar to HTN-ICH but demonstrates more severe parenchymal damage and higher ICH recurrence risk.
Plasma Phosphorylated Tau 217 as a Discriminative Biomarker for Cerebral Amyloid Angiopathy.
Hsieh P, Tsai H, Liu C, Lee B, Tsai Y, Yen R Eur J Neurol. 2025; 32(2):e70066.
PMID: 39907306 PMC: 11795418. DOI: 10.1111/ene.70066.
Characterizing the underlying microangiopathy of deep cerebellar intracerebral hemorrhage.
Das A, Abramovitz Fouks A, Gokcal E, Rotschild O, Pasi M, Regenhardt R J Neurol. 2025; 272(2):167.
PMID: 39853492 DOI: 10.1007/s00415-025-12905-8.
Updated imaging markers in cerebral amyloid angiopathy: What radiologists need to know.
Tanaka F, Maeda M, Kishi S, Kogue R, Umino M, Ishikawa H Jpn J Radiol. 2024; .
PMID: 39730931 DOI: 10.1007/s11604-024-01720-2.
Popescu D, Abramson J, Keins S, Mallick A, Kourkoulis C, Anderson C BMJ Neurol Open. 2024; 6(2):e000728.
PMID: 39720508 PMC: 11667396. DOI: 10.1136/bmjno-2024-000728.
Tension at the gate: sensing mechanical forces at the blood-brain barrier in health and disease.
Hansen C, Hollaus D, Kamermans A, de Vries H J Neuroinflammation. 2024; 21(1):325.
PMID: 39696463 PMC: 11657007. DOI: 10.1186/s12974-024-03321-2.